FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946694> ?p ?o ?g. }

• W4361946694 abstract "<div>AbstractPurpose:<p>GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses.</p>Experimental Design:<p>Plasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell–derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates.</p>Results:<p>Baseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (<i>P</i> = 0.007) and OS (<i>P</i> = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (<i>P</i> < 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo.</p>Conclusions:<p>The inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.</p></div>" @default.
• W4361946694 created "2023-04-05" @default.
• W4361946694 creator A5021359849 @default.
• W4361946694 creator A5022840912 @default.
• W4361946694 creator A5025271372 @default.
• W4361946694 creator A5031078301 @default.
• W4361946694 creator A5031945893 @default.
• W4361946694 creator A5032022793 @default.
• W4361946694 creator A5037380551 @default.
• W4361946694 creator A5044586794 @default.
• W4361946694 creator A5055050872 @default.
• W4361946694 creator A5057221032 @default.
• W4361946694 creator A5059468772 @default.
• W4361946694 creator A5061736280 @default.
• W4361946694 creator A5062010101 @default.
• W4361946694 creator A5062151371 @default.
• W4361946694 creator A5065411475 @default.
• W4361946694 creator A5067271290 @default.
• W4361946694 creator A5067763531 @default.
• W4361946694 creator A5074848009 @default.
• W4361946694 creator A5081561534 @default.
• W4361946694 creator A5085019158 @default.
• W4361946694 creator A5000358836 @default.
• W4361946694 date "2023-03-31" @default.
• W4361946694 modified "2023-10-17" @default.
• W4361946694 title "Data from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218" @default.
• W4361946694 doi "https://doi.org/10.1158/1078-0432.c.6528411" @default.
• W4361946694 hasPublicationYear "2023" @default.
• W4361946694 type Work @default.
• W4361946694 citedByCount "0" @default.
• W4361946694 crossrefType "posted-content" @default.
• W4361946694 hasAuthorship W4361946694A5000358836 @default.
• W4361946694 hasAuthorship W4361946694A5021359849 @default.
• W4361946694 hasAuthorship W4361946694A5022840912 @default.
• W4361946694 hasAuthorship W4361946694A5025271372 @default.
• W4361946694 hasAuthorship W4361946694A5031078301 @default.
• W4361946694 hasAuthorship W4361946694A5031945893 @default.
• W4361946694 hasAuthorship W4361946694A5032022793 @default.
• W4361946694 hasAuthorship W4361946694A5037380551 @default.
• W4361946694 hasAuthorship W4361946694A5044586794 @default.
• W4361946694 hasAuthorship W4361946694A5055050872 @default.
• W4361946694 hasAuthorship W4361946694A5057221032 @default.
• W4361946694 hasAuthorship W4361946694A5059468772 @default.
• W4361946694 hasAuthorship W4361946694A5061736280 @default.
• W4361946694 hasAuthorship W4361946694A5062010101 @default.
• W4361946694 hasAuthorship W4361946694A5062151371 @default.
• W4361946694 hasAuthorship W4361946694A5065411475 @default.
• W4361946694 hasAuthorship W4361946694A5067271290 @default.
• W4361946694 hasAuthorship W4361946694A5067763531 @default.
• W4361946694 hasAuthorship W4361946694A5074848009 @default.
• W4361946694 hasAuthorship W4361946694A5081561534 @default.
• W4361946694 hasAuthorship W4361946694A5085019158 @default.
• W4361946694 hasBestOaLocation W43619466942 @default.
• W4361946694 hasConcept C121608353 @default.
• W4361946694 hasConcept C126322002 @default.
• W4361946694 hasConcept C142724271 @default.
• W4361946694 hasConcept C143998085 @default.
• W4361946694 hasConcept C185592680 @default.
• W4361946694 hasConcept C204787440 @default.
• W4361946694 hasConcept C27081682 @default.
• W4361946694 hasConcept C2776694085 @default.
• W4361946694 hasConcept C2777088508 @default.
• W4361946694 hasConcept C2777292972 @default.
• W4361946694 hasConcept C2777802072 @default.
• W4361946694 hasConcept C2778239845 @default.
• W4361946694 hasConcept C2780427987 @default.
• W4361946694 hasConcept C2780739268 @default.
• W4361946694 hasConcept C2780804394 @default.
• W4361946694 hasConcept C2781197716 @default.
• W4361946694 hasConcept C2781451048 @default.
• W4361946694 hasConcept C55493867 @default.
• W4361946694 hasConcept C71924100 @default.
• W4361946694 hasConceptScore W4361946694C121608353 @default.
• W4361946694 hasConceptScore W4361946694C126322002 @default.
• W4361946694 hasConceptScore W4361946694C142724271 @default.
• W4361946694 hasConceptScore W4361946694C143998085 @default.
• W4361946694 hasConceptScore W4361946694C185592680 @default.
• W4361946694 hasConceptScore W4361946694C204787440 @default.
• W4361946694 hasConceptScore W4361946694C27081682 @default.
• W4361946694 hasConceptScore W4361946694C2776694085 @default.
• W4361946694 hasConceptScore W4361946694C2777088508 @default.
• W4361946694 hasConceptScore W4361946694C2777292972 @default.
• W4361946694 hasConceptScore W4361946694C2777802072 @default.
• W4361946694 hasConceptScore W4361946694C2778239845 @default.
• W4361946694 hasConceptScore W4361946694C2780427987 @default.
• W4361946694 hasConceptScore W4361946694C2780739268 @default.
• W4361946694 hasConceptScore W4361946694C2780804394 @default.
• W4361946694 hasConceptScore W4361946694C2781197716 @default.
• W4361946694 hasConceptScore W4361946694C2781451048 @default.
• W4361946694 hasConceptScore W4361946694C55493867 @default.
• W4361946694 hasConceptScore W4361946694C71924100 @default.
• W4361946694 hasLocation W43619466941 @default.
• W4361946694 hasLocation W43619466942 @default.
• W4361946694 hasOpenAccess W4361946694 @default.
• W4361946694 hasPrimaryLocation W43619466941 @default.
• W4361946694 hasRelatedWork W2020359429 @default.
• W4361946694 hasRelatedWork W2036093957 @default.
• W4361946694 hasRelatedWork W2057246093 @default.
• W4361946694 hasRelatedWork W2080607747 @default.
• W4361946694 hasRelatedWork W2093727844 @default.

• next